Fenofibrate in the treatment of dyslipidemia associated with HIV infection

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 8, 2010, Pages 995-1004

  Samineni, Divya ^a   Fichtenbaum, Carl J ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dyslipidemia; Fenofibrate; Fibric acid derivatives; HIV; Hypertriglyceridemia; Lipid lowering agents

Indexed keywords

CERIVASTATIN; CHOLESTEROL; COUMARIN ANTICOAGULANT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FENOFIBRATE; FENOFIBRIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN; NELFINAVIR; NEVIRAPINE; RITONAVIR; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; LUNG DISEASE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; VIROTHERAPY; BLOOD; COMPLICATION; CORONARY DISEASE; DRUG EFFECTS; DYSLIPIDEMIAS; HIV INFECTIONS; RISK FACTOR;

ANTI-HIV AGENTS; CHOLESTEROL, HDL; CORONARY DISEASE; DYSLIPIDEMIAS; FENOFIBRATE; HIV INFECTIONS; HUMANS; HYPOLIPIDEMIC AGENTS; RISK FACTORS; TRIGLYCERIDES;

EID: 77954859988     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.504715     Document Type: Review

References (76)

1. World Health Statistics, 2009. World Health Organization. Available from: http://www.who.int/ whosis/whostat/EN-WHS09-Full.pdf
2. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003
3. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995;75(17):1196-1201
4. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-72
5. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-2099
6. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15(2):231-239
7. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24(6):416-420
8. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74(5):1045-1052
9. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76(6):1423-1427
10. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289(22):2978-2982
11. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-705
12. Shor-Posner G, Basit A, Lu Y, et al. Hypercholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-519
13. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70
14. Gallant JE, DeJesus E, Arribas J; for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260
15. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292(2):191-201
16. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004;1:64-74
17. Fichtenbaum CJ. Do antiretrovirals increase or decrease the risk of cardiovascular disease. Curr HIV/AIDS Rep 2010;7:92-98
18. Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009;37:65-77
19. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276:37514-37519
20. DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356(17):1723-1735
21. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008;49(Suppl 2):S79-85
22. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497
23. Smith SC, Allen J, Blair SN, et al.; for the AHA/ACC and the National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute [published correction appears in Circulation.2006;113:e847]. Circulation 2006;113:2363-2372 (Pubitemid 43947981)
24. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37(5):613-627
25. Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999;33(10):1083-1103
26. Fenofibric acid United States Package Insert. December 15, 2008. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/ 022224s000lbl.pdf
27. Aberg JA, Zackin RA, Evans SR, et al. A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087 AIDS Hum Retroviruses 2005;21:757-767
28. Viljoen A, Wierzbicki AS. Potential options to treat hypertriglyceridemia. Curr Drug Targets 2009;10(4):356-362
29. De Truchis P, Kirstetter M, Perier A, et al.; for the VIH Study Group. Reduction in triglyceride levels with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 2007;44:278-285
30. Wohl DA, Tien H-C, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acids) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005;41:1498-1504
31. Gerber JG, Kitch DW, Fichtenbaum CJ, et al.; for the ACTG A5186 Team. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 Protocol. JAIDS 2008;47:459-466
32. Dube MP, Wu JW, Aberg JA, et al.; AIDS Clinical Trials Group A5148 Study Team. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11(8):1081-1089
33. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007;67(1):121-153
34. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004;6(2):148-157
35. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-2093
36. Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16(6):763-772
37. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7(1):53-58
38. Mardones P, Pilon A, Bouly M, et al. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 2003;278(10):7884-7890
39. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006;42(1):39-64
40. Koh KK, Han SH, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28(6):1419-1424
41. Rosenson RS, Huskin AL, Wolff DA, et al. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008;198(2):381-388
42. Paumelle R, Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008;18(3):73-78
43. Fenofibrate United States Package Insert. Revised March 2008. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/ 021695s006lbl.pdf
44. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-162
45. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30(11):1280-1287
46. Tojcic J, oit-Biancamano MO, Court MH, et al. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 2009;37(11):2236-2243
47. Prueksaritanont T, Richards KM, Qiu Y, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005;22(1):71-78
48. Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982;31(1):51-54
49. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418
50. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-27
51. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317(20):1237-1245
52. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366:1849-1861
53. Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010;31(1):92-99
54. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on the progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study (DAIS), a randomized study. Lancet 2001;357:905-910
55. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95(4):462-468
56. Athyros VG, Papageorgiou AA, Athyrou W, et al. Atorvastatin and micronized fenofibrate alone and in combination in Wpe 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198-1202
57. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26(9):897-905
58. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009;204:208-215
59. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009;157:195-203
60. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-522
61. Badiou S, Merle De Boever C, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172(2):273-279
62. Rao A, D'Amico S, Balasubramanyam A, Maldonado M. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004;6:315-318
63. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745-749
64. Normen L, Frohlich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diab Care 2004;9:2241-2242
65. de Luis DA, Bachiller P, Aller R. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. Nutrition 2001;5:414-415
66. Caramelli B, de Bernoche CY, Sartori AM, et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Br J Infect Dis 2001;6:332-338
67. Palacios R, Santos J, Gonzalez M, et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:251-253
68. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;1:26-31
69. Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40(2):260-290
70. Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996;27(4):563-570
71. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95(1):120-122
72. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30(5):505-512
73. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44(9):1054-1062
74. Gustavson LE, Schweitzer SM, Koehne-Voss S, et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol 2005;45(8):947-953
75. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
76. Weil A, Caldwell J, Strolin-Benedetti M. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Dispos 1988;16(2):302-309